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Abstract
AIM
To define regional grey-matter abnormalities in schizo-
phrenia patients with poor insight (Insight-), relative to 
patients with preserved clinical insight (Insight+), and 
healthy controls. 
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Forty stable schizophrenia outpatients (20 Insight- and 20 
Insight+) and 20 healthy controls underwent whole brain 
magnetic resonance imaging (MRI). Insight in all patients 
was assessed using the Birchwood Insight Scale (BIS; a 
self-report measure). The two patient groups were pre-
selected to match on most clinical and demographic 
parameters but, by design, they had markedly distinct 
BIS scores. Voxel-based morphometry employed in SPM8 
was used to examine group differences in grey matter 
volumes across the whole brain. 
RESULTS
The three participant groups were comparable in age 
[F (2,57) = 0.34, P  = 0.71] and the patient groups did 
not differ in age at illness onset [t(38) = 0.87, P  = 0.39]. 
Insight- and Insight+ patient groups also did not differ in 
symptoms on the Positive and Negative Syndromes scale 
(PANSS): Positive symptoms [t (38) = 0.58, P  = 0.57], 
negative symptoms [t (38) = 0.61, P  = 0.55], general 
psychopathology [t (38) = 1.30, P  = 0.20] and total 
PANSS scores [t(38) = 0.21, P  = 0.84]. The two patient 
groups, as expected, varied significantly in the level of 
BIS-assessed insight [t (38) = 12.11, P  < 0.001]. MRI 
results revealed lower fronto-temporal, parahippocampal, 
occipital and cerebellar grey matter volumes in Insight- 
patients, relative to Insight+ patients and healthy controls 
(for all clusters, family-wise error corrected P  < 0.05). 
Insight+ patient and healthy controls did not differ 
significantly (P  > 0.20) from each other. 
CONCLUSION
Our findings demonstrate a clear association between 
poor clinical insight and smaller fronto-temporal, occipital 
and cerebellar grey matter volumes in stable long-term 
schizophrenia patients.
Key words: Psychosis; Insight; Grey matter volumes; 
Fronto-temporal; Neural networks; Birchwood insight 
scale 
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Poor clinical insight is the most prevalent 
symptom in patients with schizophrenia and is of gro-
wing importance due to its direct association with 
poor clinical outcomes, such as frequent relapses and 
hospital admissions. This study identified significantly 
reduced fronto-temporal, parahippocampal, occipital 
and cerebellar grey matter volumes in Insight- patients 
relative to both Insight+ patients and healthy controls. The 
involvement of multiple brain areas and corresponding 
neural networks supports the theory that clinical insight, 
as a neurological function, is not confined to specific 
neuroanatomical regions but probably a function of a 
complex neurocognitive interplay with contributions from 
multiple neural networks.
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INTRODUCTION
Nearly a century ago, Kraepelin (1919) observed that 
schizophrenia patients often had “no real understanding 
of the gravity of their disorder” and regularly disputed 
that they suffer from a mental illness[1]. In the 1930s, 
Lewis described clinical insight as having “a correct 
attitude to a morbid change in one’s self”[2,3] and low 
clinical insight is the most prevalent symptom occurring 
in about 97% of schizophrenia patients[2,4]. Impaired 
insight in schizophrenia is of growing importance due to 
its direct correlation with poor clinical outcomes, such 
as frequent relapses and hospital admissions[5], poor 
compliance with medication and treatment plans[6-8], 
severe psychopathology[9], greater suicidal tendencies 
and self-injurious behaviour[9-12]. Some studies reporting 
positive correlations between improvement in clinical 
insight and better global clinical impression and clinical 
outcome scores[13] have further suggested the adoption 
of clinical insight as a possible therapeutic target in 
schizophrenia patients[14]. 
Similarities between impaired insight in schizophrenia 
and unawareness of neurological deficits such as ano-
sognosia, first described in patients with acute brain 
lesions with left-sided hemiplegia who were unaware 
of the impairments in their paralysed limbs[15,16], led 
to the notion that both phenomena share a common 
neurological basis[17-19] and prompted investigations of 
neuroanatomical abnormalities in relation to impaired 
clinical insight in schizophrenia. Earliest studies, using 
computerized tomography (CT) scan, reported significant 
and direct associations between impaired clinical insight 
and ventricular enlargement[20], total insight scores 
and total brain volumes[21] and a linear relationship 
between global cortical atrophy and impaired clinical 
insight[22]. These studies all concluded that there is a 
significant association between whole brain volume loss 
and impaired clinical insight in schizophrenia. Structural 
magnetic resonance imaging (MRI) studies also reported 
correlations between impaired clinical insight and 
smaller regional grey matter volumes, including the 
frontal lobe, anterior cingulate cortex (ACC), posterior 
cingulate, temporal and parietal lobes[23-28]. More recently, 
correlations have been reported between impaired 
insight and smaller right posterior insula volumes[29], 
smaller grey matter volumes of the right ventro-lateral 
prefrontal cortex (PFC)[30], left ventrolateral PFC, right 
dorsolateral PFC, insula, bilateral premotor area and the 
putamen; and reduced white matter volumes of the right 
superior longitudinal fasciculum, left corona radiata, left 
forceps minor and bilateral cingulum[31]. 
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Although most studies have reported a correlation 
between brain volume loss and impaired insight, some 
studies failed to find any correlation between clinical 
insight and either ventricular or total/regional brain 
volumes[3,32,33], while others reported associations bet-
ween impaired clinical insight and increased (rather than 
decreased) right medial orbitofrontal cortex grey matter 
volumes[28], and between symptom misattribution and 
increased grey matter volumes in bilateral caudate 
regions, right thalamus, left insula, putamen and cere-
bellum[34]. Bassitt et al[35] found no significant inverse 
correlation between total or regional grey matter volumes 
and clinical insight but, contrary to their expectations, 
observed a positive correlation between degree of 
insight impairment and the left medial PFC and ACC grey 
matter volumes, which they attributed to higher doses 
of antipsychotics given to patients with impaired clinical 
insight in their sample. The marked variation in findings 
may be due to the use of different brain volumetric 
assessment techniques, the heterogeneity of clinical 
insight measures and varying clinical characteristics of 
schizophrenia patients studied[25,35,36].
The aim of the present study was to characterise 
grey matter alterations in stable long-term schizophrenia 
outpatients with impaired clinical insight by directly 
comparing them, for the first time to our knowledge, 
with schizophrenia outpatients with preserved clinical 
insight, matched on average for age, sex and relevant 
demographic and clinical characteristics. Our approach 
of utilising the two extremes of the insight distribution 
should yield the largest structural difference in relation 
to insight. We also compared how these distinct groups 
of patients might differ from healthy controls, matched 
on average on age and sex of the patient groups. Ba-
sed on the findings (where positive) of existing studies 
involving solely or predominantly chronic patient samples, 
we hypothesised that, patients with impaired insight 
(Insight-) will show smaller frontal and temporal regio-
nal grey matter volumes compared to patients with 
preserved insight (Insight+) and healthy controls. This 
hypothesis also has support from previous studies 
showing, on average, poor cognitive function in patients 
with impaired insight[25,37,38] and a positive association 
between grey matter volumes of these regions and a 
range of cognitive functions in schizophrenia[39].
MATERIALS AND METHODS
Participants and study design
This study included 60 right-handed participants. Forty 
of these were patients with a diagnosis of schizophrenia, 
confirmed using the Structured Clinical Interview for 
DSM-IV (SCID)[40]. The patients formed two groups 
of 20 patients each, pre-selected to have preserved 
and impaired insight, out of a larger pool of 70 stable 
community patients. The assessment of insight and 
differentiating criteria are described in detail under 
“clinical assessment”. All included patients were required 
to be: (1) on well established antipsychotic medication 
doses for ≥ 3 mo; (2) in the stable (chronic) phase of 
the illness; and (3) ≥ 2 years from illness onset. Twenty 
healthy controls screened to exclude neuropsychiatric 
conditions and matched, on average, for age and sex 
of the patients were studied for comparison purposes. 
Ethics approval was granted by the ethics committee 
of the Institute of Psychiatry and South London and 
Maudsley Foundation NHS Trust, London. All participants 
provided written informed consent.
Clinical assessment
Birchwood Insight Scale (BIS)[41], a self-rated question-
naire, was used to assess insight in all patients. The BIS 
measures three different aspects of clinical insight[2]: 
(1) the awareness of the presence of a mental disorder 
(2nd and 7th statement); (2) the awareness of the need 
for treatment (3rd, 6th statement); and (3) the ability to 
label symptoms as abnormal (1st and 8th statement). 
Each individual BIS statement (8 in total) is rated and 
given a score of one for unsure, and either 0 or 2 for 
agree and disagree, depending on whether agreeing 
with the statement depicts preserved clinical insight (all 
statements are corrected for response valence). As we 
did not include any inpatients, Item 4 “My stay in hospital 
is necessary” was deleted, thus yielding a maximum 
possible score of 14, compared with a maximum possible 
score of 16 in the full scale BIS. In operationalising the 
BIS, Birchwood et al[41] classified preserved insight as 
having a minimum score of 9 (out of 14). In this study, 
we defined “preserved insight” as a minimum score of 
13 (out of 14) and “impaired insight” as a score of 8 or 
below. This rather conservative method was designed to 
ensure that the two groups had distinct levels of insight 
and also to eliminate those with partial clinical insight 
levels. All patients were supervised during the completion 
of the BIS. The BIS has acceptable internal consistency 
(α = 0.75) and one week test-retest reliability (r = 0.90 
for the total score[41]), and insight assessed on the BIS 
correlates positively with scores on other measures of 
insight[10,26,42]. For sample characterization purposes, 
symptoms in patients were assessed using the Positive 
and Negative Syndrome Scales (PANSS[43]). In addition, 
predicted IQ of all study participants was measured using 
the National Adult Reading Test (NART[44]).
Image acquisition and processing 
Whole brain MRI scans were acquired for all study 
participants using a 1.5 Tesla GE NV/I Signa system 
(General Electric, Milwaukee WI, United States) at the 
Maudsley Hospital, London. A series of sagittal fast 
gradient echo scout images were obtained to correct 
for head tilt and to orient subsequent images relative to 
the anterior-commissure/posterior-commissure line and 
the interhemispheric fissure. A 3-D inversion recovery 
prepared fast spoiled GRASS sequence was applied to 
acquire T1-weighted images in the axial plane with 1.5 
mm contiguous sections (TR = 18 ms, T1 = 450 ms, 
TE = 5.1 ms, flip angle = 20o with one data average 
and a 256 × 256 × 128 voxel matrix). Acquisition 
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psychopathology [t(38) = 1.30, P = 0.20] and total 
PANSS symptoms [t(38) = 0.21, P = 0.84]. Patients in 
the two groups were on a range of typical and atypical 
antipsychotics (Table 1) but received, on average, 
similar doses of antipsychotic medication [t(38) = 0.86, 
P = 0.40]. The Insight+ patient group, confirming our 
insight-based pre-selection, had significantly higher BIS 
score than the Insight- group [t(38) = 12.11, P < 0.001].
MRI: Group effects in regional grey matter volumes
Group differences in brain MRI grey matter volumes are 
presented in Table 2, and described below.
Insight- vs Insight+ patients: Compared to Insight- 
patients, Insight+ patients had larger grey matter 
volumes in the inferior frontal and precentral gyri, 
superior and middle temporal gyri, parahippocampus, 
cuneus and cerebellum of both cerebral hemispheres 
(Figure 1).
Healthy controls vs Insight- patients: Compared 
to Insight- patients, healthy controls had larger grey 
matter volumes in the left inferior and middle frontal 
gyri, left superior, middle and inferior temporal gyri, 
left parahippocampus, right cerebellum, and bilateral 
superior, middle and inferior occipital gyri (Figure 1).
Healthy controls vs Insight+ patients: There were 
no significant differences between healthy controls and 
Insight+ patients.
Group differences after co-varying for education and 
predicted IQ
Differences in grey matter volumes (noted earlier) 
between healthy controls and Insight- patients remained 
present but with reduced significance when we co-
varied for education and IQ (Table 3). Group differences 
between Insight- and Insight+ patients, however, were 
not affected. 
DISCUSSION
In this study, we directly compared two matched groups 
of schizophrenia patients but with distinct levels of clinical 
insight (Insight- vs Insight+) and investigated how they 
differ from each other and also from healthy controls in 
regional grey matter volumes examined using voxel-
based morphometry (VBM) technique. We tested the 
hypothesis that Insight- patients will show smaller frontal 
and temporal grey matter volumes compared to Insight+ 
patients. All three participant groups were comparable 
in age and the two patient groups were similar in all 
demographic and clinical parameters, including age at 
illness onset, years of education, NART IQ, symptoms 
(PANSS scores) and doses of medication prescribed. 
Insight- patients, however, had lower IQ and fewer years 
in education than healthy controls. Although, on average, 
lower IQ as well as deficits in many specific cognitive 
parameters were selected employing a sophisticated 
image simulation[45]. All MRI images were converted 
into ANALYZE format (ANALYZE software, BRU, Mayo 
Foundation, Rochester, MN) and pre-processed using 
Statistical Parametric Mapping (SPM8; http://wwwfil.ion.
ucl.ac.uk/spm) running in MATLAB 2006a (MathWorks, 
Natick, MA). Customised T1-weighted templates of the 
whole brain, grey matter, white matter and cerebro-
spinal fluid (CSF) were created for patient and healthy 
participant groups separately, and also for the whole 
study sample combined.
Statistical analysis
Demographic and clinical measures: Possible 
group differences in age, education and NART IQ were 
examined using analyses of variance (ANOVAs), and 
significant Group effects were followed by independent 
sample t-tests. Possible differences between the 
two patient groups in clinical variables (age at illness 
onset, PANSS symptom scores and medication) were 
examined using independent sample t-tests. All stati-
stical analyses were conducted using SPSS 22, with 
alpha level for significance testing maintained at P ≤ 
0.05 (two-tailed), unless stated otherwise.
MRI: Group differences (healthy controls vs Insight- 
patients, health controls vs Insight+ paitents, and Insight+ 
vs Insight- patients) in grey matter volumes, across 
the whole brain, were examined using ANOVA in SPM8 
(height threshold P < 0.005; familywise-error (FWE)-
corrected at the cluster level P < 0.05). To rule out the 
possibility that any observed group differences were due 
to trend-level Group differences in education and IQ (see 
RESULTS, demographic and clinical measures), group 
differences in grey matter volumes were re-evaluated 
using analysis of co-variance, with education and IQ 
entered as co-variates. 
RESULTS
Demographic and clinical characteristics 
The three participant groups did not differ in age [F(2,57 
= 0.34, P = 0.71]. There were trend level effects of 
Group in years of education [F(2,57) = 2.60, P = 0.08] 
and NART IQ [F(2,57) = 2.67, P = 0.08]. Healthy 
controls spent more years in education than Insight- 
patients [t(38) = 2.11, P = 0.04] but differed only at 
a trend level when compared with Insight+ patients 
[t(38) = 1.77, P = 0.08]. Healthy controls also had 
higher NART IQ than Insight- patients [t(38) = 2.47, 
P = 0.02] but did not differ from Insight+ patients 
[t(38) = 1.19, P = 0.24]. There were no significant 
differences the Insight- and Insight+ patient groups in 
education [t(38) = 0.06, P = 0.95] and NART IQ [t(38) 
= 1.04, P = 0.31] (Table 1). The two patient groups 
were similar in age at illness onset [t(38) = 0.87, P = 
0.39], positive symptoms [t(38) = 0.58, P = 0.57], 
negative symptoms [t(38) = 0.61, P = 0.55], general 
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domains in patients with schizophrenia, relative to the 
healthy population, are commonly reported[46], our study 
suggests that this may be particularly true for those 
with impaired insight[37] and in turn may also explain 
the finding of significantly fewer years in education in 
the Insight- (but not Insight+) patient group, compared 
with the healthy controls. The patient groups scored 
at opposing ends of the BIS scale; this allows for the 
interpretation of observed neuroanatomical differences in 
relation to clinical insight levels of the respective patient 
group.
As hypothesized, we found that Insight- patients had 
smaller grey matter volumes than Insight+ patients, 
bilaterally in the frontal and temporal lobes (mainly in 
the inferior frontal and precentral gyri and superior and 
middle temporal gyri), as well as in the parahippocamal 
gyrus, occipital lobes (including the cuneus) and the 
cerebellum. Insight- patients also showed similar grey 
matter deficits, particularly on the left, when compared 
to healthy controls (Figure 1).
Our findings of smaller fronto-temporal regional 
grey matter volumes are in accordance with previous 
imaging studies, that used the “Region of Interest” (ROI) 
approach and found a significant and direct correlation 
between smaller frontal areas, including the dorsolateral 
PFC, inferior frontal and middle frontal gyri[22,26-28,47,48] 
and impaired clinical insight. Early reports of poor 
executive functioning in schizophrenia patients with 
impaired insight, similar to those with frontal lobe lesions, 
initiated the interest in the integrity of the frontal lobe 
in schizophrenia. Since then, several studies[26,30,31,47], 
including this one, have reported frontal neuroanatomical 
abnormalities in relation to impaired clinical insight in 
schizophrenia. Some functional imaging studies have 
further associated aberrant frontal functional MRI activity 
with impaired clinical insight during working memory[49], 
self-reflection[50], self-monitoring[51] and self-awareness 
tasks[52] in schizophrenia. In addition, earlier correlational 
VBM studies have also reported associations between 
smaller superior and middle temporal lobe grey matter 
volumes and impaired clinical insight[23,48].
Our other finding of smaller cuneus and occipital 
grey matter volumes in Insight- patients is also broadly 
in agreement with the earlier reported association 
between poor symptom relabelling dimension of 
clinical insight and smaller grey matter volumes of the 
precuneus, cuneus and medial occipital gyrus by Morgan 
et al[25]. Unlike Morgan et al[25], we did not investigate 
preferential or predominant contribution of particular 
insight dimensions because the BIS subscale scores in 
our sample were highly positively correlated with each 
other (rho = 0.50-0.882; P < 0.001). This might be due 
to our sampling methods that ensured that our Insight- 
and Insight+ patient groups had markedly different 
insight levels, possibly in all domains. Other VBM studies 
have also reported an association between the smaller 
precuneus grey matter volumes and lower insight in 
schizophrenia[23]. The role of the precuneus has been 
described in the facilitation of increased awareness into 
one’s mental states[23,53] and has also been implicated, 
in conjunction with other midline structures, in the self-
appraisal processes[54,55]. Compared to anterior cortical 
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Table 1  Demographics and clinical characteristics of the study groups
Healthy controls (n  = 
20; 15 male, 5 female)
Patients insight+ group (n  = 20; 
16 male, 4 female)
Patients insight- group (n  = 20; 16 
male, 4 female)
Mean (SD) Range Mean (SD) Range Mean (SD) Range
Demographics
Age (yr)     35.25 (10.93) 20-59   36.15 (10.54) 19-54   37.80 (7.85) 22-49
Education (yr)   15.05 (2.86) 10-20 13.45 (2.86) 9-20   13.40 (2.01) 11-19
Predicted IQ (NART) 113.10 (9.91) 91-128 109.20 (10.80) 86-122 106.10 (7.87) 90-119
Clinical characteristics
BIS 11.65 (0.57) 13-14     5.88 (2.05) 1-8
Age at illness onset (yr) 25.90 (8.72) 13-48   23.85 (5.84) 10-37
PANSS positive symptoms 16.15 (5.38) 8-25   17.05 (4.43) 8-23
PANSS negative symptoms 17.20 (4.38) 7-27   18.15 (5.46) 8-27
PANSS general psychopathology 34.35 (7.36) 24-56   31.55 (6.27) 21-40
PANSS total symptoms   67.70 (14.90) 43-108    66.75 (14.02) 37-86
Medication (chlorpromazine equivalent in mg)   461.21 (333.95) 100-1600    556.63 (366.49) 200-1367
Medication type
Atypical antipsychotics 18 (9 olanzapine, 5 
risperidone, 3 clozapine, 
1 quetiapine)
13 (7 olanzapine, 3 
clozapine, 1 aripiprazole, 1 
amisulpride, 1 risperidone)
Typical antipsychotics 2 (1 sulpiride, 1 
haloperidol)
5 (2 flupenthixol, 1 
fluphenazine, 1 sulpiride, 1 
haloperidol)
Both -- 2 (1 on clozapine + 
levomepromazine, 
1 zuclopenthixol + 
aripiprazole)
NART: National Adult Reading Test[44]; BIS: Birchwood insight scale[41]; PANSS: Positive and negative syndrome scale[43].
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regions, much less is known about the involvement of 
posterior medial cortices due to the dearth of research 
into the contributions of these brain regions to various 
aspects of psychotic disorders[25]. In our recent study, we 
found further evidence of functional contributions from 
the precuneus, as well as the cerebellum, in supporting 
neural activities sub-serving the preservation of insight in 
schizophrenia patients[49].
There have been previous reports of cerebellar 
atrophy, on average, in schizophrenia patients[56]. A 
previous study[48] also observed a significant association 
between impaired clinical insight and reduced bilateral 
316WJP|www.wjgnet.com September 22, 2016|Volume 6|Issue 3|
Table 2  Group differences in grey matter volumes (height threshold P  < 0.005)
Groups BA Size Side MNI T  value Cluster P  FWE-corrected unless in italics Voxel P  FWE-corrected
X Y Z
Insight+ > Insight- patients
Superior temporal gyrus 22   46555 R  63   -3    5 4.91    0.001 0.020
 45  20 -33 4.74 0.034
 66   -8    4 4.68 0.040
Precentral gyrus   4  66   -5  22 4.55 0.057
Inferior frontal gyrus 47  54  19    0 4.52 0.063
Precentral gyrus   6  64    0  26 4.40 0.088
Postcentral gyrus 43  66   -8  16 4.33 0.106
parahippocampus 28  14    0 -27 4.07 0.406
Inferior frontal gyrus 47 103898 L -41  15   -6 4.81 < 0.001 0.027
Middle frontal gyrus   9 -37  19  35 4.74 0.034
Inferior frontal gyrus 47 -37  15 -10 4.73 0.035
-35  20 -10 4.54 0.059
Precentral gyrus 44 -59    8    7 4.39 0.091
Superior temporal gyrus 22 -62   -4    8 4.36 0.097
Precentral gyrus   6 -60    4    6 4.33 0.107
Middle temporal gyrus 21 -35   -3 -23 4.27 0.126
parahippocampal gyrus 20 -34   -5 -28 4.16 0.166
Cuneus 18   35993 L   -5 -83    5 4.43    0.003 0.082
Cerebellum - R  35 -90 -17 4.26 0.129
Cuneus 18 R  26 -93 -18 3.90 0.305
Cerebellum - R    4 -61    2 3.88 0.317
Cuneus 18 R    5 -98  10 3.50 0.630
R    5 -96    3 3.44 0.674
Cerebellum - L -36 -82 -15 3.38 0.730
Insight- > Insight+ patients
Nil significant
Healthy controls > Insight- patients
Inferior frontal gyrus 47   35300 L -49  19   -3 4.63    0.004 0.046
Superior temporal gyrus 22 -60    1    3 4.30 0.115
Inferior frontal gyrus 47 -41  18   -5 4.21 0.144
-38  22   -8 4.19 0.153
-36   -1 -14 3.86 0.333
Inferior temporal gyrus 20 -28 -14 -41 3.61 0.530
Parahippocamal gyrus 34 -13    4 -23 3.58 0.552
Middle frontal gyrus 11 -42  40 -19 3.39  0.722
Inferior occipital gyrus 18   11168 L -38 -92   -2 4.51    0.034 0.065
Middle occipital gyrus 19 -52 -76 -10 4.29 0.117
-48 -80 -14 3.96 0.266
-49 -81    7 3.90 0.302
Middle temporal gyrus 39/ -53 -72  22 3.37 0.740
19 -52 -74  18 3.33 0.768
-49 -76  20 3.29 0.797
Cerebellum -   25235 R  35 -90 -17 4.46    0.016 0.074
(posterior lobe)  11 -90 -37 4.21 0.146
Occipital lobe 18  23 -94 -18 4.01 0.238
Cerebellum  34 -85 -40 3.93 0.355
(posterior lobe)  38 -82 -41 3.91 0.489
Insight- patients > healthy controls
Nil significant
Healthy control > Insight+ patients
Nil significant
Insight+ patients > healthy controls 
Nil significant
BA: Brodmann area; L: Left; R: Right; MNI: Montreal Neurological Institute.
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cerebellar grey matter volumes in schizophrenia, and 
that this relationship was not associated with any 
specific dimension of clinical insight. Other studies have 
described the involvement of the cerebellum in higher 
cognitive functioning, with its extensive connectivity 
with limbic structures, including the parahippocampal 
gyrus, and associated cortical areas involved in cog-
nition and executive function[57,58], and this has been 
implicated in the neuropathology of schizophrenia and 
poor clinical insight[48,59]. Our recent finding of increased 
cerebellar activity, detected using fMRI, in Insight+ 
patients compared to Insight- patients, during a working 
memory task, also indicated cerebellar involvement in 
the preservation of clinical insight in schizophrenia[49].
In accordance with the observations made by 
other studies, we also found grey matter reductions in 
many areas in Insight- patients, compared to healthy 
controls[48]. These differences remained, but became less 
significant, after we co-varied for education and NART IQ. 
Co-varying for education and NART IQ had no effects on 
grey matter volume differences between preserved and 
Insight- patient groups, most likely because these two 
groups were comparable on these parameters.
Strengths and limitations
We employed a direct comparison method between 
distinct groups of schizophrenia patients (Insight- and 
Insight+) with closely matched demographic and clinical 
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Table 3  Group differences in grey matter volumes after co-varying for education and National Adult Reading Test IQ (height 
threshold P  < 0.005)
Groups BA Size Side MNI T  value Cluster P FWE-corrected unless shown in italics Voxel P FWE-corrected
X Y Z
Insight+ > Insight- patients
Superior Temporal gyrus 22 37261 R  63   -3    5 4.70    0.002 0.044
 45  20 -33 4.56 0.066
 66   -8    4 4.45 0.088
Precentral gyrus   4  66   -5  22 4.44 0.092
Inferior frontal gyrus 47  54  19    0 4.39 0.103
Precentral gyrus   6  64    0  26 4.28 0.137
Postcentral gyrus 43  66   -8  16 4.15 0.192
Inferior frontal gyrus 47 65047 L -42  16   -4 4.65 < 0.001 0.050
-38  14   -8 4.65 0.052
-36  18 -10 4.52 0.073
Middle frontal gyrus   9 -37  19  35 4.52 0.073
Superior temporal gyrus 22 -61   -2    7 4.28 0.139
Precentral gyrus 44 -59    9    9 4.17 0.184
Parahippocampual gyrus 21 -34   -3 -36 4.10 0.213
Cuneus 18 24291 L   -5 -83    5 4.32    0.014 0.125
Cerebellum - R  35 -90 -17 4.17 0.181
Cuneus 18 R  26 -93 -18 3.73 0.466
Cerebellum - R    4 -61    2 3.80 0.409
Cuneus 18 R    5 -98  10 3.35 0.787
Medial frontal gyrus 10 16854 L    0  60    3 3.98    0.050 0.285
Superior frontal gyrus   9    0  51  26 3.64 0.544
Insight- > Insight+ patients
Nil significant
Healthy controls > Insight- patients
Inferior frontal gyrus 47   9770 L -51  19   -2 3.68    0.036 0.511
Superior temporal gyrus 38 -21    5 -24 3.35 0.786
Inferior frontal gyrus 47 -26  18   -7 3.34 0.796
Parahippocampal gyrus 34 -16    4 -23 3.29 0.827
Inferior occipital gyrus 18   4935 L -38 -92   -2 3.92    0.122 0.323
Middle occipital gyrus 19 -52 -76 -10 3.70 0.494
-44 -83    8 3.37 0.775
Middle temporal gyrus 18 -43 -81   13 3.22 0.873
Cerebellum (posterior lobe) -   6085 R  35 -90 -17 3.68    0.089 0.304
 11 -90 -37 3.60 0.378
Occipital lobe 18  28 -94 -16 3.32 0.656
 23 -94 -18 3.26 0.713
Insight- patients > healthy controls
Nil significant
Healthy controls > Insight+ patients
Nil significant
Insight+ patients > healthy controls 
Nil significant
BA: Brodmann area; L: Left; R: Right; MNI: Montreal Neurological Institute.
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qualities, thereby facilitating valid comparisons and 
inferences. The study also had 60 participants (n = 20 
per group) and thus was adequately powered for the 
observations made. We were, however, limited in our 
ability to explore the effects of sex on brain volumes 
and in the observed group differences, as our sample 
was predominantly male. Nonetheless, male:female 
ratios were similar and any possible effect is expected 
to be uniform in all groups. Also, although the patient 
groups were comparable in all relevant areas, our 
healthy controls had more education than our patient 
groups, and had higher IQ scores than Insight- patient 
group, although co-varying for these differences did not 
change the pattern of observed group differences. By 
adopting a direct comparison method between matched 
patient groups at the extremes of insight measures, we 
minimised confounding effects of partial insight levels and 
were able to exclude overall effects of schizophrenia on 
brain volumes. However, in as much as we endeavoured 
that our two patient groups are highly comparable but 
for their insight levels, there are possibilities of other 
differential properties, such as brain functional properties, 
which could possibly contribute to our findings. Lastly, 
patients in both the Insight+ and Insight- groups were on 
a range of atypical and typical antipsychotics (Table 1) 
which vary in their pharmacological profiles[60,61] as well 
as in their effects on brain volumes[62]. This may have 
influenced the results we observed in this study.
In conclusion, schizophrenia patients with impaired 
insight patients have smaller fronto-temporal, parahi-
ppocampal, occipital and cerebellar grey matter volumes, 
compared with preserved insight schizophrenia patients 
and healthy controls. The involvement of multiple brain 
areas and corresponding neural networks supports the 
theory that clinical insight, as a neurological function, is 
not confined to specific neuroanatomical regions in the 
brain but probably a function of a complex neurocognitive 
interplay with contributions from neural networks, 
including working memory and executive functioning, 
self-monitoring and awareness and others[19,23,49,63,64].
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